Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma.
Authors
Chen, RAllibone, Suzanne
Bartlett, N
Brice, P
Chen, A
Pose, K
Rich, L
Bonthapally, V
Garfin, P
Fanale, M
Affiliation
Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USAIssue Date
2016
Metadata
Show full item recordAbstract
Patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) or R/R systemic anaplastic large-cell lymphoma (sALCL) treated with brentuximab vedotin (BV) experienced high remission rates in two Phase II trials. With increased response rates and survival times, patient-reported outcomes (PROs) and health-related quality of life (HRQoL) are becoming increasingly important and can help inform treatment decisions to enhance care of cancer patients.Citation
Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma. 2016, 9:2027-34 Onco Targets TherJournal
OncoTargets and TherapyDOI
10.2147/OTT.S96175PubMed ID
27103829Type
ArticleLanguage
enISSN
1178-6930ae974a485f413a2113503eed53cd6c53
10.2147/OTT.S96175
Scopus Count
Collections
Related articles
- Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients.
- Authors: Gandolfi L, Pellegrini C, Casadei B, Stefoni V, Broccoli A, Tonialini L, Morigi A, Argnani L, Zinzani PL
- Issue date: 2016 Dec
- Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study.
- Authors: Izutsu K, Ogura M, Tobinai K, Hatake K, Sakamoto S, Nishimura M, Hoshino M
- Issue date: 2021 Mar
- The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
- Authors: Gravanis I, Tzogani K, van Hennik P, de Graeff P, Schmitt P, Mueller-Berghaus J, Salmonson T, Gisselbrecht C, Laane E, Bergmann L, Pignatti F
- Issue date: 2016 Jan
- Cost-effectiveness of brentuximab vedotin for relapsed or refractory systemic anaplastic large-cell lymphoma in China.
- Authors: Liu J, Zheng L, Chuang LH
- Issue date: 2022 Jan-Dec
- Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.
- Authors: Newland AM, Li JX, Wasco LE, Aziz MT, Lowe DK
- Issue date: 2013 Jan